Cargando…

Toward Drug-Like Multispecific Antibodies by Design

The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawant, Manali S., Streu, Craig N., Wu, Lina, Tessier, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589779/
https://www.ncbi.nlm.nih.gov/pubmed/33053650
http://dx.doi.org/10.3390/ijms21207496
_version_ 1783600657660379136
author Sawant, Manali S.
Streu, Craig N.
Wu, Lina
Tessier, Peter M.
author_facet Sawant, Manali S.
Streu, Craig N.
Wu, Lina
Tessier, Peter M.
author_sort Sawant, Manali S.
collection PubMed
description The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is not optimal for many therapeutic applications, and this has led to the design of a vast number of unique multispecific antibody formats that enable targeting of multiple antigens or multiple epitopes on the same antigen. Despite the diversity of these formats, a common challenge in generating multispecific antibodies is that they display suboptimal physical and chemical properties relative to conventional IgGs and are more difficult to develop into therapeutics. Here we review advances in the design and engineering of multispecific antibodies with drug-like properties, including favorable stability, solubility, viscosity, specificity and pharmacokinetic properties. We also highlight emerging experimental and computational methods for improving the next generation of multispecific antibodies, as well as their constituent antibody fragments, with natural IgG-like properties. Finally, we identify several outstanding challenges that need to be addressed to increase the success of multispecific antibodies in the clinic.
format Online
Article
Text
id pubmed-7589779
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75897792020-10-29 Toward Drug-Like Multispecific Antibodies by Design Sawant, Manali S. Streu, Craig N. Wu, Lina Tessier, Peter M. Int J Mol Sci Review The success of antibody therapeutics is strongly influenced by their multifunctional nature that couples antigen recognition mediated by their variable regions with effector functions and half-life extension mediated by a subset of their constant regions. Nevertheless, the monospecific IgG format is not optimal for many therapeutic applications, and this has led to the design of a vast number of unique multispecific antibody formats that enable targeting of multiple antigens or multiple epitopes on the same antigen. Despite the diversity of these formats, a common challenge in generating multispecific antibodies is that they display suboptimal physical and chemical properties relative to conventional IgGs and are more difficult to develop into therapeutics. Here we review advances in the design and engineering of multispecific antibodies with drug-like properties, including favorable stability, solubility, viscosity, specificity and pharmacokinetic properties. We also highlight emerging experimental and computational methods for improving the next generation of multispecific antibodies, as well as their constituent antibody fragments, with natural IgG-like properties. Finally, we identify several outstanding challenges that need to be addressed to increase the success of multispecific antibodies in the clinic. MDPI 2020-10-12 /pmc/articles/PMC7589779/ /pubmed/33053650 http://dx.doi.org/10.3390/ijms21207496 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sawant, Manali S.
Streu, Craig N.
Wu, Lina
Tessier, Peter M.
Toward Drug-Like Multispecific Antibodies by Design
title Toward Drug-Like Multispecific Antibodies by Design
title_full Toward Drug-Like Multispecific Antibodies by Design
title_fullStr Toward Drug-Like Multispecific Antibodies by Design
title_full_unstemmed Toward Drug-Like Multispecific Antibodies by Design
title_short Toward Drug-Like Multispecific Antibodies by Design
title_sort toward drug-like multispecific antibodies by design
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589779/
https://www.ncbi.nlm.nih.gov/pubmed/33053650
http://dx.doi.org/10.3390/ijms21207496
work_keys_str_mv AT sawantmanalis towarddruglikemultispecificantibodiesbydesign
AT streucraign towarddruglikemultispecificantibodiesbydesign
AT wulina towarddruglikemultispecificantibodiesbydesign
AT tessierpeterm towarddruglikemultispecificantibodiesbydesign